5 FU LOADED LIPOSOMES FOR CANCER TREATMENT

Abstract

Cancer remains a formidable challenge in modern medicine, necessitating innovative and targeted therapeutic approaches to improve outcomes for patients. Among
the myriad strategies employed, 5-Fluorouracil (5-FU) has emerged as a potent chemotherapeutic agent due to its ability to disrupt DNA synthesis and inhibit cell
proliferation. However, the clinical utility of 5-FU is limited by its non-specific distribution, rapid clearance, and dose-dependent toxicities.In response to these
challenges, researchers have explored nanotechnology-based drug delivery systems as a promising avenue to enhance the therapeutic efficacy of 5-FU while
minimizing its adverse effects.In active loading, drug internalization into preformed liposomes is typically driven by a transmembrane pH gradient. The pH outside
the liposome allows some of the drug to exist in a unionized form, able to migrate across the lipid bilayer. 5 mg of 5Fu is loaded in lipid bilayer and stirred for 4
hours.5-fluorouracil (5-FU) is a chemotherapeutical agent used to treat cancers including breast and colorectal. Working as an antimetabolite to prevent cancer cell
proliferation, it primarily inhibits the enzyme thymidylate synthase blocking the thymidine formation required for DNA synthesis. Liposomes are widely used as
carriers for anticancer drugs due to their ability to prolong the retention of encapsulated drugs in blood plasma while directing their distribution increasingly into
tumor tissue. In conclusion, 5-FU loaded liposomes hold significant promise in revolutionising cancer treatment. Their potential to improve drug delivery, minimize
side effects, and enable personalized therapeutic strategies underscores the importance of continued research and development in this field. However, addressing
challenges and ensuring the safety and efficacy of these formulations are critical steps towards their successful clinical implementation